Rob D Prince
Research Subjects
Rob D Prince has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- April M. Barbour
Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, 709 Swedeland Rd. UW2431, King of Prussia, Pennsylvania, 19406, USA,
1 shared publication - Beat M. Jucker
Bioimaging, GSK, Collegeville, PA, United States
1 shared publication - Elena DeAngelis
Innovation BDU, Biopharm Research, Cambridge, UK
1 shared publication - Gavin X Jones
Innovation BDU, Biopharm Research, Cambridge, UK
1 shared publication - John J. Lepore
Metabolic Pathways and Cardiovascular Therapy Area, GlaxoSmithKline, King of Prussia, PA, USA
1 shared publication - Karpagam Aravindhan
Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, PA 19406, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 148
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Glucagon-like peptide-1 (GLP-1) and its mimetics reduce infarct size in the setting of acute myocardial ischemia/reperfusion (I/R) injury. However, the short serum half-life of GLP-1 and its mimetics may limit their therapeutic use in acute myocardial ischemia. Domain antibodies to serum albumin (AlbudAbs) have been developed to extend the serum half-life of short lived therapeutic proteins, peptides and small molecules. In this study, we compared the effect of a long acting GLP-1 agonist, DPP-IV resistant GLP-1 (7–36, A8G) fused to an AlbudAb (GAlbudAb), with the effect of the GLP-1 mimetic, exendin-4 (short half-life GLP-1 agonist) on infarct size following acute myocardial I/R injury.
- 1 January 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 148
Open AccessNovel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Glucagon-like peptide-1 (GLP-1) and its mimetics reduce infarct size in the setting of acute myocardial ischemia/reperfusion (I/R) injury. However, the short serum half-life of GLP-1 and its mimetics may limit their therapeutic use in acute myocardial ischemia. Domain antibodies to serum albumin (AlbudAbs) have been developed to extend the serum half-life of short lived therapeutic proteins, peptides and small molecules. In this study, we compared the effect of a long acting GLP-1 agonist, DPP-IV resistant GLP-1 (7–36, A8G) fused to an AlbudAb (GAlbudAb), with the effect of the GLP-1 mimetic, exendin-4 (short half-life GLP-1 agonist) on infarct size following acute myocardial I/R injury.